Heart Failure

Just weeks after it fast-tracked dapagliflozin for the treatment of chronic kidney disease, the FDA announced it was granting Fast Track status to the drug for another indication: heart failure.

Researchers have successfully trained a convolutional neural network to detect congestive heart failure with 100% accuracy using data from just one heartbeat.

Research presented at the ESC Congress in Paris Sept. 2 suggests malaria could be linked to as much as a 30% increased risk of heart failure.

Research out of the Netherlands suggests current clinical guidelines might recommend overtreatment for women with heart failure, who see maximum benefit from HF drugs at half the dose of men.

Using donor hearts from patients who died of traumatic brain injury might be a more viable option for transplant candidates than previously thought, according to an analysis published in the Journal of the American Heart Association Aug. 30.

SGLT2 inhibitors—namely dapagliflozin—have been linked to a reduced risk of heart failure and death, as well as decreased odds of major adverse cardiovascular events.

Oregon Health & Science University will resume its heart transplant services this month after nearly a year of inactivity, the university announced Aug. 26.

Childhood cancer survivors are up to three times more likely than their cancer-free peers to develop various types of heart disease, according to an Aug. 26 study published in Circulation.

A multi-country study in Asia has revealed patients with both type 2 diabetes and heart failure face higher odds of structural CV abnormalities, a poorer quality of life and an increased risk of death.

Istaroxime, a dual action, luso-inotropic agent that’s still in clinical development, was granted fast-track designation by the FDA this month as a possible treatment for HFrEF.

The FDA on August 16 granted breakthrough designation to CVRx Inc.’s Barostim Neo System, a device meant to improve heart failure symptoms in patients unsuited for other therapies like CRT. 

Biopharmaceutical company Renovacor, Inc., on August 14 announced it had raised $11 million in Series A financing to further develop its gene therapy-based treatments for CVD.